Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: LarryS who wrote (6634)	7/8/1998 9:10:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

Larry, thanks for the alert. Anyone have any comments on this statement by XOMA? "..., our first approvals could well be for small indications, like meningococcemia or cystic fibrosis, ......." I found it interesting that while Trauma is in P III and C.F. is in a very small P I that this statement was made. Yes, the Trauma trial is large and is expected to take at least until July 2,000. Yes the C.F. application may get some sort of fast track and orphan drug status. Guess I was just not thinking that it in any way was considered an application that might make prior to Neuprex for trauma. Obviously, the above relates only to submission for approval, not approval itself, which is in the hands of the F.D.A. I try not to step on my own questions but in this case I was not sure if it would be at all clear what I was asking about.